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PCV74
MEASURING HEALTH RELATED QUALITY OF
LIFE AFTER STROKE
Lopez Bastida J1, Serrano Aguilar P1, Monton Alvarez F2,
Duque González B1
1Canarian Health Service, Santa Cruz de Tenerife, S/C de
Tenerife, Spain; 2Ntra. Sra. de la Candelaria, Universitary
Hospital, Santa Cruz de Tenerife, S/C de Tenerife, Spain
OBJECTIVES: The EQ-5D is a multiattribute health
status measure that can be used to derive preferences-
based index scores for HRQL assessment. The objective
of the study was to elicit the Visual Analogue Scale (VAS)
and the Time Trade-off (TTO) scores of minor (indepen-
dent after stroke) and major (dependent after stroke)
stroke survivors, from social tariffs obtained from general
population samples. METHODS: A cross-sectional study
of 350 stroke survivors was conducted in Spain. They
were stratiﬁed as minor and major stoke, depending 
if they required help from another person for everyday
activities. The EQ-5D questionnaire was administered 
to stroke survivors. Responses to the questionnaire were
converted in single scores along a continuum extending
from death (0.0) to full health (1.0). RESULTS: The VAS
and the TTO scores varied considerably across minor and
major stroke survivors. The minor and major stroke sur-
vivor, mean VAS scores were 0.71 (0.23) and 0.33 (0.27)
respectively and mean for TTO scores were 0.73 (0.28)
and 0.21 (0.43) respectively. Minor and major stroke 
survivors were a signiﬁcant predictor of VAS and TTO
scores. CONCLUSIONS: Minor and major stroke sur-
vivors had a substantial inﬂuence on VAS and TTO
scores, as measured by the EQ-5D. Patients with major
stroke had much lower scores. Our data support the
EuroQol as a useful measure of health status after stroke.
Its simplicity is a deﬁnite advantage, because many stroke
survivors ﬁnd more complex instruments difﬁcult to com-
plete without help.
PCV75
PROJECTED LIFE YEAR GAINED AND OTHER
BENEFITS OF EZETIMIBE CO-ADMINISTRATION
IN CHD PATIENTS NOT ATTAINING TOTAL
CHOLESTEROL GOAL WITH STATIN
MONOTHERAPY IN FINLAND
Cook JR1,Alemao E2,Veltri E3,Yin DD4
1Merck Research Labs, Blue Bell, PA, USA; 2Merck and Co,
Whitehouse Station, NJ, USA; 3Schering Plough
Pharmaceutical, Kenilworth, NJ, USA; 4Merck & Co., Inc,
Whitehouse Station, NJ, USA
OBJECTIVE: To project the impact of Ezetimibe 10mg
(EZ10) co-administration for typical CHD patient not
attaining TC goal with simvastatin 10mg (S10)
monotherapy in Finland on remaining life expectancy,
mean TC reduction, and percent reaching goal.
METHOD: A decision-analytic model is used to project
beneﬁts of lipid therapy. Clinical trial data on the distri-
bution of TC changes was used to project the percent of
patients reaching TC goal with ezetimibe co-administered
with current statin therapy compared to titration (up 
to the maximum approved dose of Simvastatin 80mg) to
attain goal TC. Impact of TC changes on life expectancy
was projected using Framingham risk equations and non-
coronary mortality rates from Statistics Finland. In the
base case the model was run for a 55 year old male on
treatment with S10 and having TC = 6mmol/L, and HDL
= 1.1mmol/L. The beneﬁts were also obtained for men
and women aged 35 to 75 years with TC 5.5 to 
8.0mmol/L. RESULTS: For a 55-year-old male CHD
patient with TC = 6mmol/L while on S10, Ezetimibe co-
administration with simvastatin is projected to increase
the remaining life expectancy from 10.8 to 11.24 years
compared to statin titration where 42% not at goal are
titrated at each dose (titration strategy I) and from 11.09
to 11.24 years compared to statin titration where all
patients not at goal were titrated to attain goal (titration
strategy II). Projected additional patients at TC goal per
100 treated and mean TC reduction are 10 and 3.66%
for titration strategy I, 57 and 14.5% for titration strat-
egy II, and 65 and 18.28% for EZ10 co-administration
with S10. CONCLUSION: For the patient proﬁle studied
EZ10 co-administration with current statin is projected
to bring more patients to goal and may increase survival
time compared to titrating statin.
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IS THE MLHF QUESTIONNAIRE VALID FOR
INTERNATIONAL MULTICENTRIC STUDIES?
Garin O1, Ferrer M1, Pont A1,Wiklund I2,Van Ganse E3,
Pietri G3, Lobo-Luppi L4,Alonso J1
1Institut Municipal d’Investigació Mèdica, (IMIM-IMAS),
Barcelona, Cataluña, Spain; 2Astra Hässle Research
Laboratoris, Möelndal, Sweden; 3Lyon Sud Hospital, Lyon,
France; 4for the IQOD group, Mapi Research Institute, Lyon,
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OBJECTIVE: Most of Health Related Quality of Life
(HRQL) questionnaires were developed in English lan-
guage countries and their use is extended to other coun-
tries after adaptation. However, with few exceptions,
little is known about scores equivalence across countries.
Minnesota Living with Heart Failure Questionnaire
(MLHFQ) is a widely used speciﬁc HRQL instrument 
for patients suffering from heart failure. For this disorder,
the New York Heart Association classiﬁcation (NYHA)
is the usual severity indicator. The aim of this study 
was to assess the MLHFQ scores for each NYHA class
and equivalence across countries. METHODS: Data
came from 13 countries (2780 individuals). A general
lineal model (adjusted by age and gender) was con-
structed to conﬁrm whether or not MLHFQ scores 
and NYHA class were consistent across countries (USA
as reference). Interaction between these variables was
included. To check differences between countries also
Bonferroni pair wise multiple contrast was applied.
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RESULTS: The MLHFQ showed similar metric proper-
ties across the studied countries; Cronbach’s alpha 
internal consistency was above the standard proposed 
for individual comparisons (0.9) for all countries. The
general lineal model showed that MLHFQ scores vary by
age, gender, and NYHA class (p < 0.001), that the inter-
action between scores and functional capacity was not
signiﬁcant (p = 0.363); only Australia and Italy’s scores
differed signiﬁcantly (p = 0.003). Adjusted means of
MLHFQ score were: 31 (95% CI 28.6–33.2), 44 (95%
CI 42.4–45.8), and 58 (95% CI 51.8–64.1); for class II,
III and IV respectively (class I sample was not enough to
deﬁne a reference score). CONCLUSIONS: These results
suggest that MLHFQ scores are comparable across 
countries (excepting Australia and Italy which will need
further research), allowing their use in international 
multicentric studies.
PCV77
THE ECONOMIC ASSESSMENT OF LIPID
LOWERING THERAPY WITH EZETIMIBE IN
SPAIN
Davies GM1, Cook JR1, Nocea G2,Veltri E3,Alemao E4,
Yin DD4
1Merck Research Labs, Blue Bell, PA, USA; 2Merck Sharp &
Dohme, España, Madrid, Spain, Spain; 3Schering Plough
Pharmaceutical, Kenilworth, NJ, USA; 4Merck & Co., Inc,
Whitehouse Station, NJ, USA
While treatment guidelines recommend lowering choles-
terol to target levels, many remain above recommended
goal (LDL-C >= 100mg/dl). In a clinical trial, 72% of the
patients who received ezetimibe co-administered with
existing statin therapy reached NCEP II goal versus 19%
among patients who continued statin monotherapy.
OBJECTIVES: To assess cost-effectiveness of ezetimibe
10mg (EZ10) co-administration with simvastatin 10mg
(S10) versus a simvastatin dose titration strategy in
CHD/CHD equivalent patients (deﬁned in NCEP III
guidelines) who do not attain goal with S10 alone.
METHOD: A decision-analytic model was developed to
project lifetime costs and beneﬁts of lipid therapy. Clini-
cal trial data were used to estimate LDL-C reductions for
different treatment strategies. The effect of LDL-C reduc-
tions on CHD event rates was estimated using Framing-
ham equations and Spanish Instituto Nacional de
Estadística data on nonCHD-related mortality. Direct
costs of CHD events in Spain, Spanish prices for generic
simvastatin and EZ 10 price (based on German EZ10
price) were used to project lifetime costs. The model was
run for a population consisting of all patients in an obser-
vational lipid lowering treatment study in Spain who
started treatment with S10 and had not reached goal at
the ﬁrst LDL-C measurement after 60 days of treatment.
RESULTS: For these patients (mean age 62 years, 32%
male, 36% CHD & 64% CHD equivalent patients, base-
line LDL-C 148mg/dl), EZ10 co-administered with S10
compared to simvastatin titration is projected to increase
life expectancy by 0.23 years with a C/LY of €20,178.
The incremental cost per additional patient to goal in the
ﬁrst year was €1748 per year. CONCLUSION: Based on
the model, treatment with EZ10 co-administered with
S10 for patients not at goal is a cost-effective alternative
to statin titration, well under the limit C/LY of €30,000
considered acceptable in Spain.
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QUALITY OF LIFE IN CHRONIC PATHOLOGIES
IN PRIMARY CARE
Leiva F1, Garcia Ruiz AJ2, Martos Crespo F2,
Prados Torres JD1, Sanchez de la Cuesta F2
1Family Practice Department, Malaga, Spain;
2PharmacoEconomics and Outcomes Research Unit, Malaga,
Spain
OBJECTIVES: 1) Compare the patients health perceived
between diagnosed of COPD, arterial hypertension
(HTA) and diabetes mellitus (DM) in Primary Care; and
2) to analyze the sociodemographics features associate 
to the quality of life (QOL) in these chronic pathologies.
METHOD: Cross-sectional descriptive study, from
2000–2002. We selected a random systematic sample:
624 hypertension ones, 148 HTA + DM and 278 COPD.
Dependent variable: Each patient fulﬁll the Nottingham
Health Proﬁle (NHP). Independent variables: age, gender,
educational level, marital status, labour situation. Statis-
tical analysis: descriptive (mean ± SD, absolute and 
relative frequencies) and bivariante analysis (ANOVA).
RESULTS: Age: COPD (66,9 ± 8,9 years); HTA (64,7 ±
10,3); HTA + DM (69,6 ± 9,6). Gender: male 88%; 40%
and 23% (in COPD, HTA and HTA + DM respectively).
Homogenous distribution between educational level,
labour situation retirement and marital status between
groups. NHP: in HTA + DM population and COPD she
is similar, with the exception of the dimensions social 
isolation, (higher score in the COPD) and pain (greater
score in the HTA + DM). Relation between sociodemo-
graphics characteristics and health perceived: the QOL
perceived is worse in the women than in the men (p <
0,05). To greater age, worse physical mobility (p < 0,05);
exists a positive relation between the labour situation
(activity) and physical mobility of patients EPOC and for
all the factors valued by the NHP in the HTA patients.
The educational levels are inﬂuences positively in the 
perception of certain areas of the QOL in HTA (all) 
and HTA + DM (pain, emotional reactions, physical
mobility and total NHP). Married being repels of favor-
able way in concrete aspects of the QOL of patients
COPD (sleep, social isolation and health) and in all those
of the HTA ones patients. CONCLUSION: Any subject
affection of a chronic pathology perceives a health worse
than the general population. The sociodemographics 
features inﬂuence more in those patients than they present
less symptomatic pathologies (HTA), that those that
suffers more symptomatic diseases (COPD or HTA +
DM).
